Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyPeter Connick, Siddharthan Chandran, Ming‐Qing Du et al.|The Lancet Neurology|2012Cited by 606
Cell-based therapeutic strategies for multiple sclerosisNeil Scolding, Stefano Pluchino, Marcelo C. Pasquini et al.|Brain|2017Cited by 169
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Siddharthan Chandran, Madhan Kolappan et al.|Trials|2011Cited by 119